Developer docs
API playgroundTry for free, no card

Search company profiles

Prostatype Genomics AB

Full company profile

uuid0004ngr

Namestring
Prostatype Genomics AB
Legal namestring
Prostatype Genomics AB
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Prostatype Genomics AB is a Swedish medical technology company founded in 2007 and headquartered in Solna, Sweden, that manufactures, markets, and sells Prostatype, a proprietary prognostic gene test for prostate cancer. The company is publicly listed on the Stockholm Stock Exchange under the ticker sto:PROGEN and operates with a small team of 1-10 employees, targeting healthcare providers — specifically urologists and oncologists — as its primary customer segment.

The core product, Prostatype, is positioned as a prognostic gene test, implying analysis of gene-expression signatures to forecast prostate cancer outcomes and inform treatment decisions; however, the source material does not disclose the underlying algorithm, biomarker panel, or laboratory workflow. No patents, certifications, or product-level technical details are enumerated in the available data, and the technology block characterizes the firm only as a "medical technology company focused on prostate cancer diagnostic solutions."

Commercially, the company has yet to disclose a pricing model, revenue, or named customers. It has funded operations through equity issuances — a warrant exercise in April 2024 raising approximately SEK 7.3 million (~81% subscription) and a planned SEK 47 million preferential rights issue in July 2026 conditional on a Medicare-related regulatory milestone — with capital earmarked for US market entry. The company serves the Nordic region from its home market and is actively pursuing entry into the United States, supported by a dedicated US-based President and a Chief Medical Officer.

Short descriptiontext

Prostatype Genomics AB is a Swedish publicly listed medtech company (sto:PROGEN) that develops and sells the Prostatype prognostic gene test for prostate cancer, serving urologists and oncologists in the Nordics while pursuing US market entry.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
prostate cancer diagnostics, prognostic gene tests, medical diagnostics, oncology testing, urology diagnostics
Industry2 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Medical Laboratories621511
Product category
Prostate Cancer Diagnostics
Cost components4 values
Technology or R&D, Marketing or Sales, Operations, Personnel
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Prostatype Genomics AB is a Swedish medical technology company that manufactures, markets, and sells Prostatype, a prognostic gene test used by urologists and oncologists to support prostate cancer diagnosis and treatment decisions. The company is actively strengthening its market entry into the United States following recent capital raises through warrant exercises and rights issues.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Prostatype
CategoryPrognostic Cancer Diagnostics
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MDxHealth markets SelectMDx and ConfirmMDx, two of the most direct commercially available prostate cancer genomic tests. It is the closest head-to-head competitor to Prostatype, competing for the same urologist customer and similar payor coverage pathways.

TypeDirect peer
Description

Veracyte's Decipher Prostate genomic classifier is a prognostic test used by urologists to guide treatment decisions after prostate cancer diagnosis. It is one of the most clinically validated competitors in the same prognostic niche Prostatype targets.

TypeDirect peer
Description

Myriad has a long-standing genetic-testing franchise including Prolaris (prostate cancer prognostic test). It competes with Prostatype in the same prognostic space with deeper payor coverage and an established US sales force.

TypeDirect peer
Description

Exact Sciences, through its acquisition of Genomic Health, markets Oncotype DX Genomic Prostate Score, a directly comparable prognostic gene-expression test for prostate cancer. It is one of the most well-capitalized and commercially entrenched peers in this category.

TypeDirect peer
Description

OPKO Health's 4Kscore test is a blood-based prostate cancer diagnostic used by urologists to aid biopsy decisions. It is a directly comparable commercial prostate cancer diagnostic, even though it is positioned earlier in the diagnostic pathway than Prostatype.

TypeDirect peer
Description

Guardant Health is a leader in oncology genomics with liquid biopsy and tissue-based genomic profiling products. It overlaps with Prostatype in the broader oncology genomic-testing category and represents a potential competitor or strategic acquirer as it expands into prognostic and treatment-decision applications.

TypeBroad incumbent
Description

NeoGenomics is a large US-based oncology-focused clinical laboratory offering a broad menu of molecular and genetic tests, including for prostate cancer. It is a much larger, broader incumbent in the oncology testing space and is comparable as a go-to-market reference for US oncology diagnostics.

TypeBroad incumbent
Description

Foundation Medicine, owned by Roche, provides comprehensive genomic profiling of tumors. While not focused on prostate prognostic testing specifically, it is a broad incumbent in oncology genomics and sets the bar for clinical evidence and payor coverage in the category.

TypeDirect peer
Description

NanoString developed the Decipher GRID and PAM50-based gene-expression assays used in oncology, including prostate cancer prognostic applications. It is comparable as a technology platform for gene-expression-based prognostic tests aimed at urologic oncology.

TypeEmerging player
Description

Strand Life Sciences is an emerging genomics and clinical diagnostics company with a growing oncology and hereditary cancer testing portfolio. It is comparable as a smaller, multi-product genomics company navigating similar clinical-evidence and payor-coverage challenges in oncology diagnostics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prostatype Genomics AB

Prostate Cancer Diagnosticsprostatypegenomics.com

Prostatype Genomics AB is a Swedish publicly listed medtech company (sto:PROGEN) that develops and sells the Prostatype prognostic gene test for prostate cancer, serving urologists and oncologists in the Nordics while pursuing US market entry.

What Prostatype Genomics AB does

Prostatype Genomics AB is a Swedish medical technology company founded in 2007 and headquartered in Solna, Sweden, that manufactures, markets, and sells Prostatype, a proprietary prognostic gene test for prostate cancer. The company is publicly listed on the Stockholm Stock Exchange under the ticker sto:PROGEN and operates with a small team of 1-10 employees, targeting healthcare providers — specifically urologists and oncologists — as its primary customer segment.

The core product, Prostatype, is positioned as a prognostic gene test, implying analysis of gene-expression signatures to forecast prostate cancer outcomes and inform treatment decisions; however, the source material does not disclose the underlying algorithm, biomarker panel, or laboratory workflow. No patents, certifications, or product-level technical details are enumerated in the available data, and the technology block characterizes the firm only as a "medical technology company focused on prostate cancer diagnostic solutions."

Commercially, the company has yet to disclose a pricing model, revenue, or named customers. It has funded operations through equity issuances — a warrant exercise in April 2024 raising approximately SEK 7.3 million (~81% subscription) and a planned SEK 47 million preferential rights issue in July 2026 conditional on a Medicare-related regulatory milestone — with capital earmarked for US market entry. The company serves the Nordic region from its home market and is actively pursuing entry into the United States, supported by a dedicated US-based President and a Chief Medical Officer.

Prostatype Genomics AB firmographics

Firmographics
Name
Prostatype Genomics AB
Legal name
Prostatype Genomics AB
Website
https://prostatypegenomics.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
1–10 employees
Short description
Prostatype Genomics AB is a Swedish publicly listed medtech company (sto:PROGEN) that develops and sells the Prostatype prognostic gene test for prostate cancer, serving urologists and oncologists in the Nordics while pursuing US market entry.
Ownership category
akta.pro rank

Prostatype Genomics AB industry classification

Industry
Product category
Prostate Cancer Diagnostics
NAICS
Medical Laboratories (621511)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Prostate cancer diagnostics
  • Prognostic gene tests
  • Medical diagnostics
  • Oncology testing
  • Urology diagnostics

Where Prostatype Genomics AB is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Markets served

Prostatype Genomics AB business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Marketing or Sales, Operations, Personnel

Prostatype Genomics AB product offering

Product offering

Core offering

Prostatype Genomics AB is a Swedish medical technology company that manufactures, markets, and sells Prostatype, a prognostic gene test used by urologists and oncologists to support prostate cancer diagnosis and treatment decisions. The company is actively strengthening its market entry into the United States following recent capital raises through warrant exercises and rights issues.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prostatype

Companies that use Prostatype Genomics AB

Customer profile

Segments1 record

Ideal customer profiles1 record

Prostatype Genomics AB technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Prostatype Genomics AB partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Prostatype Genomics AB competitors and assessment

Company assessment

Direct peers

  • MDxHealth: MDxHealth markets SelectMDx and ConfirmMDx, two of the most direct commercially available prostate cancer genomic tests. It is the closest head-to-head competitor to Prostatype, competing for the same urologist customer and similar payor coverage pathways.
  • Veracyte (Decipher Biosciences): Veracyte's Decipher Prostate genomic classifier is a prognostic test used by urologists to guide treatment decisions after prostate cancer diagnosis. It is one of the most clinically validated competitors in the same prognostic niche Prostatype targets.
  • Myriad Genetics: Myriad has a long-standing genetic-testing franchise including Prolaris (prostate cancer prognostic test). It competes with Prostatype in the same prognostic space with deeper payor coverage and an established US sales force.
  • Exact Sciences (Genomic Health): Exact Sciences, through its acquisition of Genomic Health, markets Oncotype DX Genomic Prostate Score, a directly comparable prognostic gene-expression test for prostate cancer. It is one of the most well-capitalized and commercially entrenched peers in this category.
  • OPKO Health (4Kscore): OPKO Health's 4Kscore test is a blood-based prostate cancer diagnostic used by urologists to aid biopsy decisions. It is a directly comparable commercial prostate cancer diagnostic, even though it is positioned earlier in the diagnostic pathway than Prostatype.
  • Guardant Health: Guardant Health is a leader in oncology genomics with liquid biopsy and tissue-based genomic profiling products. It overlaps with Prostatype in the broader oncology genomic-testing category and represents a potential competitor or strategic acquirer as it expands into prognostic and treatment-decision applications.
  • NanoString Technologies: NanoString developed the Decipher GRID and PAM50-based gene-expression assays used in oncology, including prostate cancer prognostic applications. It is comparable as a technology platform for gene-expression-based prognostic tests aimed at urologic oncology.

Broad incumbents

  • NeoGenomics: NeoGenomics is a large US-based oncology-focused clinical laboratory offering a broad menu of molecular and genetic tests, including for prostate cancer. It is a much larger, broader incumbent in the oncology testing space and is comparable as a go-to-market reference for US oncology diagnostics.
  • Foundation Medicine (Roche): Foundation Medicine, owned by Roche, provides comprehensive genomic profiling of tumors. While not focused on prostate prognostic testing specifically, it is a broad incumbent in oncology genomics and sets the bar for clinical evidence and payor coverage in the category.

Emerging players

  • Strand Life Sciences: Strand Life Sciences is an emerging genomics and clinical diagnostics company with a growing oncology and hereditary cancer testing portfolio. It is comparable as a smaller, multi-product genomics company navigating similar clinical-evidence and payor-coverage challenges in oncology diagnostics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Prostatype Genomics AB social profiles

Digital presence

Prostatype Genomics AB financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prostatype Genomics AB leadership team

Management profile

Number of profiles

Profiles3 records

Prostatype Genomics AB funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prostatype Genomics AB M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prostatype Genomics AB

What does Prostatype Genomics AB do?

Prostatype Genomics AB is a Swedish medical technology company that manufactures, markets, and sells Prostatype, a prognostic gene test used by urologists and oncologists to support prostate cancer diagnosis and treatment decisions. The company is actively strengthening its market entry into the United States following recent capital raises through warrant exercises and rights issues.

Is Prostatype Genomics AB a public or private company?

Prostatype Genomics AB is a private company. It is classified as public and is currently operating.

When was Prostatype Genomics AB founded?

Prostatype Genomics AB was founded in 2007. It employs 1 to 10 people.

Where is Prostatype Genomics AB based?

Prostatype Genomics AB is headquartered in Stockholm, Sweden, in the Europe region.

Who are Prostatype Genomics AB's main competitors?

Direct peers on record are MDxHealth, Veracyte (Decipher Biosciences), Myriad Genetics, Exact Sciences (Genomic Health), OPKO Health (4Kscore), Guardant Health and NanoString Technologies. Broad incumbents are NeoGenomics and Foundation Medicine (Roche). Strand Life Sciences is listed as an emerging player.

Does Prostatype Genomics AB have an API?

No public API is recorded for Prostatype Genomics AB.

What industry is Prostatype Genomics AB in?

Prostatype Genomics AB's product category is Prostate Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 621511.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingInterview with the CEO of Prostatype GenomicsFredrik Rickman, CEO of Prostatype Genomics, discussed new long-term data showing added value for the company's genetic test Prostatype over the NCCN risk classification. He also addressed ongoing Medicare reimbursement in the US, with a working meeting scheduled for early November.Dagens industriProstatype tar in 12,5 miljoner i företrädesemissionProstatype Genomics raised about 12.5 million SEK from the exercise of subscription options. The company issued 125 million options in July 2026, exercisable at 0.10 SEK each between September 1 and 15, 2026.TradingViewProstatype Genomics AB publishes information memorandum prior to rights issue of unitsProstatype Genomics AB has published an information memorandum for a rights issue of units with a subscription period from July 9 to July 23, 2026. The company expects to receive approximately SEK 47.4 million upon full subscription, with 91.3% of the issue already covered by subscription commitments and underwriting undertakings. Net proceeds will finance the company's ongoing Medicare approval process and support commercialization activities in the United States and Europe.TradingViewProstatype Genomics AB enters into top-down underwriting ahead of upcoming rights issue of unitsProstatype Genomics AB has entered into a top-down underwriting agreement with Vator Securities AB for approximately 10.1 million SEK, securing roughly 21.3 percent of its upcoming rights issue proceeds. This commitment brings the total secured funding for the 47.4 million SEK rights issue to approximately 91.3 percent, covering both bottom-underwriting and initial subscription commitments. The company plans to conduct the rights issue in July 2026, with trading in unit rights scheduled from July 9 to 20.Bloomberg2670576D: Prostatype Genomics AB Stock Price QuoteProstatype Genomics AB manufactures and sells the prostatype gene test, which assesses prostate cancer risk. The company serves customers in Sweden. No stock price or financial data is provided.AInvestProstatype Genomics and the Growing Role of Genomic Testing in Precision OncologyProstatype Genomics has secured broad U.S. insurance coverage for its genomic classifier, with Medicare approval pending in 2025. The test's P-score achieved an AUC of 0.93 for predicting 10-year prostate cancer mortality, outperforming traditional models. Medicare approval could unlock a $13.16B market, positioning the company for rapid scaling.ProstatypegenomicsProstatype Genomics announces outcome of exercise of warrants of series 3 (TO3)Prostatype Genomics announced that approximately 81.0% of its Series 3 warrants were exercised, generating roughly SEK 7.3 million in proceeds before costs. This capital raise supports the company's planned entry into the United States market and ongoing clinical studies. The total number of shares increased by over 202 million to nearly 991 million following the exercise.news.cision.comProstatype Genomics announces outcome of exercise of warrants of series 3 (TO3)Prostatype Genomics announced that approximately 81.0 percent of its Series 3 warrants were exercised, generating proceeds of roughly SEK 7.3 million before issuing costs. This capital raise supports the company's imminent entry into the United States market and ongoing clinical studies for its prostate cancer genetic test. The exercise increased the total number of shares outstanding to over 990 million.PR NewswireNew multi-centre study in Spain shows very strong interim results for Prostatype®Prostatype Genomics reported strong interim results from a multi-centre study conducted with seven Spanish hospitals and the Spanish National Association of Urology. The analysis of 160 patients indicates that approximately 60% would have been reclassified for prognosis and treatment decisions if Prostatype® had been used, demonstrating its ability to predict disease progression. The company plans to present final data in Q1 2024 to support further clinical implementation and sales in the Spanish market.